Literature DB >> 2982963

The relation of viral replication to interstitial pneumonitis in murine cytomegalovirus lung infection.

J D Shanley, E L Pesanti.   

Abstract

Using a murine model of murine cytomegalovirus (MCMV) interstitial pneumonitis, we examined the relation between the virus content of the lung and lung disease. While MCMV alone does not cause lung disease, interstitial pneumonitis was present in all mice receiving both MCMV and a single dose of cyclophosphamide. In this case the severity of disease, judged by increases in wet weight of the lung, was proportional to the virus content of the lung. Although both acyclovir (50 mg/kg per day) and passive antibody administration reduced the MCMV titers in lung tissues by greater than 90%, histological evidence of interstitial pneumonitis was present in all animals. However, both virus inhibitors reduced the severity of interstitial pneumonitis in treated mice. While transient alterations in host immunity are necessary to induce interstitial pneumonitis after MCMV infection, the severity of interstitial pneumonitis seems to reflect the burden of virus replication. Reduction of virus growth does not prevent, but may moderate, MCMV interstitial pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982963     DOI: 10.1093/infdis/151.3.454

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Murine cytomegalovirus m02 gene family protects against natural killer cell-mediated immune surveillance.

Authors:  Sofia A Oliveira; Se-Ho Park; Peter Lee; Albert Bendelac; Thomas E Shenk
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis.

Authors:  Pali D Shah; Qiong Zhong; Elizabeth A Lendermon; Matthew R Pipeling; John F McDyer
Journal:  Viral Immunol       Date:  2015-05-18       Impact factor: 2.257

3.  Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.

Authors:  R Holtappels; J Podlech; G Geginat; H P Steffens; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 4.  Animal cytomegaloviruses.

Authors:  J Staczek
Journal:  Microbiol Rev       Date:  1990-09

5.  Cytomegalovirus inhibits the engraftment of donor bone marrow cells by downregulation of hemopoietin gene expression in recipient stroma.

Authors:  H P Steffens; J Podlech; S Kurz; P Angele; D Dreis; M J Reddehase
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Modification of acute murine cytomegalovirus adrenal gland infection by adoptive spleen cell transfer.

Authors:  J D Shanley
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

7.  Pneumonitis in bone marrow transplant recipients results from a local immune response.

Authors:  H J Milburn; R M Du Bois; H G Prentice; L W Poulter
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

8.  Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus.

Authors:  C A Stoddart; R D Cardin; J M Boname; W C Manning; G B Abenes; E S Mocarski
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

9.  Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine.

Authors:  D F Smee; J L Morris; J A Leonhardt; J R Mead; A Holy; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Correlation of interstitial pneumonia with human cytomegalovirus-induced lung infection and graft-versus-host disease after bone marrow transplantation.

Authors:  C A Müller; H Hebart; A Roos; H Roos; M Steidle; H Einsele
Journal:  Med Microbiol Immunol       Date:  1995-10       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.